GlassScriptPhysician profile
Glenn A Gorlitsky
NPI 1881625143
$8,659.43
in general payments reported to CMS, 2019-2025
42 companies · $1,110 in 2025
The $1,110 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,387 · 2020: $1,241 · 2021: $1,797 · 2022: $959 · 2023: $1,199 · 2024: $967 · 2025: $1,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,275.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,748.78 | 2019-2025 | |
| Amgen INC. | $1,084.35 | 2019-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $893.62 | 2019-2025 | |
| Lilly USA, LLC | $587.27 | 2019-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $550.98 | 2019-2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $463.00 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $382.90 | 2020-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.40 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| E.R. Squibb & Sons, L.L.C. | $259.75 | 2019-2023 | Eliquis |
| Alnylam Pharmaceuticals INC. | $258.91 | 2021-2025 | Amvuttra |
| Astellas Pharma US INC | $221.36 | 2019-2021 | |
| Almatica Pharma LLC | $182.12 | 2021-2024 | Loreev Xr, Gralise, Teriparatide |
| Eisai INC. | $174.34 | 2020-2022 | |
| Amarin Pharma, INC. | $163.09 | 2019-2021 | |
| Allergan, INC. | $158.85 | 2019-2020 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Gorlitsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.